Live attenuated African swine fever viruses as ideal tools to dissect the mechanisms involved in viral pathogenesis and immune protection by Lacasta, Anna et al.
Lacasta et al. Vet Res  (2015) 46:135 
DOI 10.1186/s13567-015-0275-z
RESEARCH
Live attenuated African swine fever 
viruses as ideal tools to dissect the mechanisms 
involved in viral pathogenesis and immune 
protection
Anna Lacasta1,2, Paula L. Monteagudo1, Ángeles Jiménez‑Marín3, Francesc Accensi1,4, María Ballester1,5, 
Jordi Argilaguet6, Iván Galindo‑Cardiel1,7, Joaquim Segalés1,4, María L. Salas8, Javier Domínguez9, 
Ángela Moreno3,10, Juan J. Garrido3 and Fernando Rodríguez1*
Abstract 
African swine fever virus (ASFV) is the causal agent of African swine fever, a hemorrhagic and often lethal porcine 
disease causing enormous economical losses in affected countries. Endemic for decades in most of the sub‑Saharan 
countries and Sardinia, the risk of ASFV‑endemicity in Europe has increased since its last introduction into Europe in 
2007. Live attenuated viruses have been demonstrated to induce very efficient protective immune responses, albeit 
most of the time protection was circumscribed to homologous ASFV challenges. However, their use in the field is 
still far from a reality, mainly due to safety concerns. In this study we compared the course of the in vivo infection 
caused by two homologous ASFV strains: the virulent E75 and the cell cultured adapted strain E75CV1, obtained from 
adapting E75 to grow in the CV1 cell‑line. Interestingly, the kinetics of both viruses not only differed on the clinical 
signs that they caused and in the virus loads found, but also in the immunological pathways activated throughout the 
infections. Furthermore, E75CV1 confirmed its protective potential against the homologous E75 virus challenge and 
allowed the demonstration of poor cross‑protection against BA71, thus defining it as heterologous. The in vitro speci‑
ficity of the CD8+ T‑cells present at the time of lethal challenge showed a clear activation against the homologous 
virus (E75) but not against BA71. These findings will be of utility for a better understanding of ASFV pathogenesis and 
for the rational designing of safe and efficient vaccines against this virus.
© 2015 Lacasta et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
African swine fever (ASF) is a highly pathogenic disease 
caused by African Swine Fever Virus (ASFV), a rather 
complex virus against which there is no vaccine available. 
Thus, eradication of the disease has relied, so far, on early 
diagnosis and subsequent culling of infected and exposed 
pigs. Only 10 years after its eradication from continental 
Europe, ASFV re-entered Europe arriving from Africa to 
the Caucasian Republic of Georgia in 2007. Since then, 
ASFV has spread to neighboring countries including 
Russia, already reaching some E.U. countries and due to 
the global commercialization exchanges existing today, 
also menacing the rest of the world [1]. The risk of ende-
micity in Eastern European countries has dramatically 
increased in recent years due to the lack of enough pre-
paredness and resources to implement successful control 
programs in the affected regions with both domestic pigs 
and wild boars being equally affected [2]. The risk of new 
introductions or reintroductions of the virus in ASF-free 
areas is high, overall taking into account the complex epi-
demiological situation of ASFV in Africa [3], with more 
than 22 genotypes currently circulating in the area [4] 
and the ease with which the virus can spread [5, 6]. With 
these antecedents at hand, having a safe and efficient 
Open Access
*Correspondence:  fernando.rodriguez@irta.cat 
1 Centre de Recerca En Sanitat Animal (CReSA), Institut de Recerca 
i Tecnologia Agroalimentàries (IRTA), Campus UAB, Bellaterra, 
08193 Barcelona, Spain
Full list of author information is available at the end of the article
Page 2 of 16Lacasta et al. Vet Res  (2015) 46:135 
vaccine might increase the chances of controlling ASF 
in the future. Work done decades ago, demonstrated 
the failure of classically inactivated vaccine in achieving 
strong protection against experimental ASF infection [7–
10]. Conversely, classically attenuated vaccines have been 
shown to be very efficient at controlling homologous 
experimental challenges, albeit in a rather limited way 
against heterologous virus challenges [11, 12]. In spite of 
their success, the use of live attenuated vaccines (LAV) in 
the field has been limited mainly due to safety problems 
derived from their inherent infectious nature [13]. More 
recently, new generation vaccines have created expecta-
tions for the future. The identification of key protective 
antigens within the ASFV genome [14] has allowed the 
possibility of attempting the design of safe DIVA vac-
cines for the future [15]. On the other hand, recombinant 
deletion of targeted virulence factors should theoretically 
permit the generation of efficient modified LAV against 
ASFV [16–18] with increased security; a field in continu-
ous progression. Independent of their safety problems, to 
date LAV have provided the most relevant data regard-
ing the mechanisms involved in ASFV-protection. Thus, 
today we know that both specific antibodies [19] and spe-
cific CD8+ T-cells [20] play crucial role in the protection 
afforded by LAV. Despite this, the mechanisms involved 
in the protection afforded by antibodies are still largely 
unknown and several mechanisms have been proposed 
[21]. Similarly, CD8+ T-cells have been postulated as a 
key T cell subset in the protection afforded by both LAV 
[20] and DNA vaccines [14, 15]. More advanced genomic 
and proteomic methodologies have opened new alterna-
tives to better understand not only the intrinsic mecha-
nisms involved in protection but also the early and late 
events implicated in viral pathogenesis. Few studies have 
been published so far using microarrays and almost all 
of them have focused on comparing the effects of ASFV 
strains with different virulence in vitro [22]. Albeit use-
ful in general terms, further work is needed using well 
characterized homologous ASFV strains to specifically 
identify individual virulence factors. As above described, 
previous results obtained in the 80s with the attenuated 
E75CV1 strain [11], demonstrated the fine balance exist-
ing between death and survival after intranasal experi-
mental infection and the capability of surviving animals 
to resist subsequent lethal challenge with the homolo-
gous virulent E75 virus. Here we have extended the use of 
the virulent E75 and its cell culture adapted counterpart 
E75CV1 to better compare the in vivo immunopathogen-
esis of both viral strains and also to understand the intrin-
sic mechanisms involved in protection afforded against 
the homologous lethal challenge. To perform these stud-
ies the optimal dose for intramuscular inoculation of 
E75CV1 was first standardized and next an experimental 
set up was designed to compare: (1) the kinetics of the 
E75 and E75CV1 viral infection, (2) the evolution of 
induced innate and specific immune responses and (3) 
the protective potential of E75CV1 against homologous 
and heterologous challenges. The sequential sampling of 
sera, nasal swabs, and lymphoid tissues together with a 
multi-technical approach allowed the further characteri-
zation of both ASFV pathogenesis and protection and 
has opened new avenues for further research.
Materials and methods
Virus strains and ethical statements
Three different ASFV strains were used in the in vivo and 
in vitro experiments: BA71, E75 and E75CV1. BA71 and 
E75 strains (both virulent) were isolated from the 1971 
and 1975 Spanish ASF outbreaks, respectively. After-
wards, they were further propagated in pig leucocytes. 
E75CV1 isolation was achieved by 4 consecutive passages 
in CV1 cells (green monkey kidney fibroblasts) [11].
Experiments with 8-week-old Landrace X Large White 
pigs (conventional farm pigs) were performed under the 
approval of the Ethical and Animal Welfare Committee 
of the Universitat Autònoma de Barcelona (UAB; Permit 
Number: DMAH-5796) and infections with ASFV were 
done under biosecurity level 3 (BSL-3) conditions at Cen-
tre de Recerca en Sanitat Animal (CReSA, Barcelona, 
Spain).
Experimental design for the in vivo experiments
Pigs were intramuscularly inoculated (i.m.i.) in the neck 
with 1  mL of the corresponding ASFV dose and virus 
strain diluted in PBS 1X pH 7.4 or with PBS 1X pH 7.4 
alone as control of the assay. Animals were observed daily 
according to a welfare schedule to monitor their health 
status and to record the clinical signs after the infection 
with ASFV [23].
Experiment 1: selecting the optimal dose 
for E75CV1‑immunization
Sixteen pigs were divided into 4 groups with 4 pigs in 
each one and received either PBS 1X pH 7.4 (control ani-
mals) or three different doses of the cell culture adapted 
strain E75CV1: 102 50% hemadsorbing units (HAU50), 
104 HAU50 and 105 HAU50.
Experiment 2: comparative kinetics of E75 and E75CV1 
infections
Fifty four pigs were divided into three groups that were 
maintained in isolation from each other: (a) 24 pigs 
were infected with the optimal dose of the attenuated 
E75CV1 ASFV strain, obtained from the experiment 
1:104 HAU50 and sequential blood sampling and necrop-
sies were performed in groups of 6 pigs at days: 1, 3, 7 
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and 31 post-infection (pi); (b) 18 pigs were infected with 
the same dose (104 HAU50) of E75, the homologous viru-
lent virus and again groups of 6 pigs were sequentially 
sampled, sacrificed and subjected to necropsy at days 1, 
3 and 7 pi; (c) finally, 12 animals remained uninfected 
and were sequentially sampled and sacrificed in groups 
of 3 at days 1, 3, 7 and 31 pi as controls. All animals were 
sampled prior to the infection (day 0 pi). During necrop-
sies all animals and organs of interest (spleen, gastro-
hepatic lymph node, liver and kidneys) were weighted 
separately in order to establish their relative weight: per-
centage of the total body weight that the specific organ 
represents.
Experiment 3: homologous versus heterologous 
ASFV‑challenge
Sixteen pigs were divided in two groups housed sepa-
rately, from this point on termed BOX-1 and BOX-2 
respectively. Four pigs from each room were i.m.i. inoc-
ulated with 104 HUA50 of the E75CV1 (optimal dose of 
immunization selected in experiment 1), and the other 
four from each box remained uninfected receiving the 
same volume of PBS 1X pH 7.4. Twenty-eight days after 
E75CV1-inoculation all pigs from BOX-1 were chal-
lenged with 104 HAU50 of the homologous E75 strain, 
and pigs from BOX-2 were challenged with 103 HAU50 
of BA71; corresponding to 20 lethal dose fifty (LD50) 
for each one of the ASFV strains ([24] and unpublished 
data).
Virus titration
Blood samples were collected before and at differ-
ent times after virus challenge for viremia quantifica-
tion using the haemadsorption technique, as previously 
described [14, 25]. Titres were calculated by the Reed and 
Muench method [26] and expressed as HAU50/mL.
A real time quantitative PCR (qPCR) method recently 
described in our laboratory [15], was used to quantify the 
viral DNA from nasal swabs-PBS suspensions and tis-
sues (gastrohepatic lymph node). Briefly, the viral DNA 
was obtained from 200 μL of swab-PBS suspensions 
using the NucleoSpin blood kit or from 25 mg of tissue 
using NucleoSpin tissue kit (both from Macherey–Nagel, 
Düren, Germany) following the manufacturer’s recom-
mendations and used as template to amplify an 85  bp-
long fragment from the ASFV serine protein kinase gene 
(R298L). PCR amplifications were performed in triplicate 
using the corresponding standards for absolute quantifi-
cation. The results were expressed as log10 genome equiv-
alent copies (GEC) per mL of nasal swab.
Additionally ASFV-infected macrophages were double-
stained using the antibodies anti-CD172a (hybridoma 
clone BA1C11), specific for monocytes and macrophages 
and anti-p30 (hybridoma clone 1D9), specific for the p30 
virus structural protein, and after secondary staining, the 
cells were FACS-analyzed [15].
Histopathology and microscopic tissue evaluation
Tissue samples (spleen, gastrohepatic lymph node, liver 
and kidneys) were previously fixed in 10% formalin 
(Sigma-Aldrich, Madrid, Spain) and embedded in par-
affin-wax for histological processing. Four μm-sections 
were stained with haematoxylin and eosin for microscop-
ical examination. Infiltration of macrophages, apoptosis 
and ASFV-antigen detection were evaluated by specific 
immunohistochemical methods as briefly described 
below. Tissue sections were incubated for 30 min in a 3% 
hydrogen peroxide solution (diluted in absolute metha-
nol) to inhibit the endogenous peroxidase. Afterwards, 
the sections were treated with EDTA (0.37  mg/mL, 
diluted in PBS 0.5% Tween20, pH 8) at 98 °C for 15 min 
and then blocked with 2% bovine serum albumin (BSA, 
Sigma-Aldrich, Madrid, Spain) for 1 h at room tempera-
ture for further specific antibody labeling. Both, primary 
and secondary antibodies were incubated for 18 h at 4 °C 
and subsequently treated with the avidin–biotin complex 
solution (ABC, Thermo Scientific, Rockford, IL, USA); 
labeling was revealed with 3,3′-diaminobenzidine (DAB, 
Sigma-Aldrich, Madrid, Spain).
Infiltrated macrophages were detected using the anti-
MAC387 rabbit-antibody (1:40, Dako, Barcelona, Spain) 
and apoptotic cells were detected using an anti-caspase-3 
rabbit-antibody (1:100, Cell Signaling Technology, Barce-
lona, Spain). In both cases the secondary antibody used 
was an anti-rabbit IgG peroxidase conjugated (1:100, 
Dako, Barcelona, Spain). ASFV-infected cells were 
detected using an anti-p30 antibody (undiluted clone 
1D9) generously provided by INIA (Madrid) and using 
as a secondary antibody an anti-mouse IgG peroxidase-
conjugated antibody (1:200, Dako, Barcelona, Spain).
Measuring specific antibody responses
ASFV specific antibodies in pig sera were detected by the 
OIE-approved ELISA assay based on the use of soluble 
extracts from ASFV infected cells [27]. The presence of 
positive sera was detected using 100 μL of peroxidase-
conjugated anti-pig IgG at 1/20 000 dilution (Sigma-
Aldrich, Madrid, Spain) as secondary antibody and 50 
μL of soluble 3,3′,5,5′-tetramethylbenzidine (TMB) as 
specific peroxidase substrate (Sigma-Aldrich, Madrid, 
Spain). Reactions were stopped with 50 μL of 1 N H2SO4 
(Sigma-Aldrich, Madrid, Spain) per well. The plates were 
read at 450  nm wavelength (λ450) and the results were 
represented as the average absorbance (optical density 
(OD) values) between duplicates. Additionally, sera were 
used to test their ability to inhibit the in  vitro infection 
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of E75 in porcine alveolar macrophages following slightly 
modified previously described protocols [28]. Briefly, 
serial dilutions of sera (1:10 and 1:20) were first comple-
ment-inactivated at 56  °C for 30 min. After inactivation 
the sera dilutions were incubated with 4 ×  105 HAU of 
E75 for 1 h at 37 °C (gently mixed every 15 min), prior to 
the infection of porcine alveolar macrophage monolayers 
(4 × 105 cells/well in a 96-well plate) for 72 h. The ASFV 
titres were finally expressed as HAU50/mL by using the 
haemadsorption technique [31].
Measuring specific T‑cell responses
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from whole blood by density-gradient centrifu-
gation with Histopaque 1077 (Sigma-Aldrich, Madrid, 
Spain). For PBMC cultures, RPMI 1640 medium supple-
mented with 10% fetal calf serum (Invitrogen, Barcelona, 
Spain), 50 000  IU penicillin/l (Invitrogen, Barcelona, 
Spain) and 50 mg streptomycin/l (Invitrogen, Barcelona, 
Spain) was used. Trypan blue was used to assess cell-
viability. The frequency of ASFV-specific IFNγ-secreting 
cells (IFNγ-SC) in PBMC was analyzed by an ELISPOT 
assay using commercial mAbs (Swine IFNγ, Cytoset; Bio-
source Europe) following a previously reported method 
[15]. PBMCs were specifically stimulated in vitro with 106 
HAU50/mL of the E75 ASFV strain for 20  h and 10  µg/
mL Phytohemaglutinin (PHA, Sigma-Aldrich, Madrid, 
Spain) was used as positive control for the assay. To cal-
culate the frequencies ASFV-specific IFNγ-SC, counts of 
spots in unstimulated wells were subtracted from counts 
in virus-stimulated wells. The frequency of cytokine-
producing cells was expressed as responding cells in 106 
PBMCs.
Alternatively, PBMCs were labeled with carboxyfluo-
rescein diacetate succinimidyl ester (CFSE, Vybrant 
CFDA SE Cell Tracer kit, Invitrogen, Barcelona, Spain), 
in vitro stimulated with 106 HAU50/mL of either the E75 
or the BA71 ASFV strains for 72  h, and finally cell via-
bility was assessed by staining with LIVE/DEAD® Fix-
able Violet Dead Cell Strain Kit (Invitrogen, Barcelona, 
Spain) and surface-labeled with anti-CD8-AlexaFluor647 
(clone 76-2-11) and anti-CD4-PerCPCy5.5 (clone 74-12-
4) antibodies (BD Pharmingen, NJ, USA), allowing the 
phenotyping of the virus-specific proliferating cells [29]. 
Combining these two markers, three different T-cell 
populations could be defined [30]: CD4+ T-cells (sin-
gle positive CD4), cytotoxic T-cells or CTLs (single 
positive CD8high) and memory T-cells (double positive 
CD4+CD8low).
Analysis of relative gene expression by qPCR
After necropsy, gastrohepatic lymph node samples 
were aseptically collected, overnight treated with 
RNAlater® (Ambion, Austin, TX, USA) at 4  °C to 
increase the RNA stability of the tissues and next fro-
zen at −80  °C for further RNA isolation. RNA was 
isolated using the RNeasy Mini kit (Qiagen, Valencia, 
CA, USA), treated with RNase-free DNase Set (Qia-
gen, Valencia, CA, USA) and impurities removed with 
RNeasy Minielute kit (Qiagen, Valencia, CA, USA), fol-
lowing the manufacturer’s instructions. The integrity, 
quality and quantity of RNA obtained was checked in 
1% (w/v) agarose gels and using a NanoDrop™ 1000 
Spectrophotometer (Thermo Scientific, Rockford, IL, 
USA). qPCR technology was used to determine the 
relative expression of a panel of 19 swine gene tran-
scripts representative of Th1, Th2 and Th17 responses 
(Table 1), previously described [31, 32]. One μg of RNA 
isolated from infected and control animals at different 
times post-infection was reverse transcribed to cDNA 
using the iScript cDNA Synthesis kit (BioRad, Her-
cules, CA, USA). Three animals from each time point 
and group were selected taking into account the qual-
ity and quantity of the RNA obtained. A PCR specific 
for the 18S was performed with all cDNAS in order to 
assess their quality. Final concentration of primers in 
the PCR reactions was 0.5  μM and primers (Table  1) 
were designed using Beacon Designer™ (Biosoft Inter-
national, Palo Alto, CA, USA) and internal normali-
zation of the gene expression analysis was carried out 
by using beta-actin and PPIA as reference genes [33]. 
The relative gene expression was assessed by the 2−ΔΔCt 
method [34] and applied as previously described [31]. 
With this method, a fold-change value of 1 or −1 repre-
sents no difference in gene expression. The differences 
in mRNA expression among groups were assessed by 
the Student’s paired T-test using SigmaPlot v10.0 (Sys-
tat Software Inc., CA, USA). Values of p  <  0.05 were 
considered as being significant.
ELISA detection of serum soluble factors
Serum samples were harvested in polypropylene tubes 
and stored at −80 °C until use. ELISA was used for serum 
interferon-α (IFN-α, R&D, Minneapolis, MN, USA) and 
tumour necrosis factor-α (TNF-α, R&D, Minneapolis, 
MN, USA), according to the manufacturer’s instruc-
tions. Respective standard curves were used to deter-
mine the amounts (U/mL in IFN-α assay and pg/mL in 
TNF-α assay) of each cytokine in the porcine serum sam-
ples. IFN-α and TNF-α amounts were measured both in 
control and infected pigs at each sampling time. Soluble 
CD163 (sCD163) was quantified in sera by a previously 
described enzyme-linked immunosorbent assay (ELISA), 
using lysates from CD163-transfected CHO cells as a 
standard, and results were expressed as the equivalent 
number of CD163-transfected cells [35].
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Results
E75CV1, an ideal experimental infection model but not a 
safe vaccine prototype
Due to the complexity of standardizing a dose for 
E75CV1 intranasal immunization, the intramuscular 
route for E75CV1 in vivo inoculation was tested (Experi-
ment 1). Therefore, 3 groups of four pigs each were i.m.i. 
with either 102 HAU50, 104 HAU50 or 105 HAU50 of the 
E75CV1 strain and deaths were recorded during the 
course of the infection. Interestingly enough, all pigs i.m.i. 
with 104 HAU50 of E75CV1 survived the infection, while 
2 out of the 4 pigs (50%) that received ten times more 
virus (105 HAU50 of E75CV1), died at days 14 and 25 pi, 
respectively (Figure  1) with clear clinical signs of acute 
ASF. Intriguingly, infection with 102 HAU50 E75CV1 (100 
times lower than the intermediate dose), also resulted 
in an unexpected course of the disease, which resolved 
with the death of 2 out of the 4 pigs by days 27 and 28 
pi (Figure 1). The 2 surviving pigs showed no detectable 
viremia and very short peaks of mild fever while fatal 
cases coincided with the first appearance of ASF clini-
cal signs by day 17 pi, correlating with the detection of 
viremia and fever (Figure  2A). Conversely, pigs suc-
cumbing after the challenge with 105 HAU50 of E75CV1 
showed viremia and fever that peaked as early as day 5 
pi, 3 days before the surviving animals that also showed 
lower and shorter viremia and fever peaks (Figure  2B). 
Finally, i.m.i. with 104 HAU of E75CV1 resulted optimal 
not only because there were no deaths (Figure 1) but also 
because pigs infected with this intermediate virus dose 
showed either no viremia and no clinical signs of acute 
ASF (in one of the pigs) or just limited viremia and fever 
episodes that reached undetectable levels by day 28 pi 
Table 1 List of genes and sequences of the primers used for qPCR analysis.
Gene name Forward primer (5′ → 3′) Reverse primer (5′ → 3′) Accession number
β‑actin CAGGTCATCACCATCGGCAACG GACAGCACCGTGTTGGCGTAGAGGT U07786
PPIA CCTGAACATACGGGTCCTG AACTGGGAACCGTTTGTGTTG AY266299
18S GACTCAACACGGGAAACCTCAC GCTTATGACCCGCACTTACTGG AY265350
TNFα CCTCTTCTCCTTCCTCCTG CCTCGGCTTTGACATTGG X57321
IL‑1β GGCCGCCAAGATATAACTGA GGACCTCTGGGTATGGCTTTC NM_214055
IL‑4 TTGCTGCCCCAGAGAAC TGTCAAGTCCGCTCAGG AY294020
IL‑5 TGGTGGCAGAGACCTTGACA CCATCGCCTATCAGCAGAGTT NM_214205.1
IL‑6 TGGCTACTGCCTTCCCTACC CAGAGATTTTGCCGAGGATG NM_214399
IL‑8 TTCGATGCCAGTGCATAAATA CTGTACAACCTTCTGCACCCA AB057440
IL‑10 CAGATGGGCGACTTGTTG ACAGGGCAGAAATTGATGAC L20001
IL‑12p40 GGAGTATAAGAAGTACAGAGTGG GATGTCCCTGATGAAGAAGC U08317
IL‑13 AAGTGGCCCAGTTCGTAAAAGA ACCCGTGGCGAAAAATCA NM_213803.1
IL‑17A CTCTCGTGAAGGCGGGAAT TCCTCAGTTTTTGGGCATCCT NM_001005729
IL‑18 AGGGACATCAAGCCGTGTTT CGGTCTGAGGTGCATTATCTGA EU118362.1
IL‑21 CTGCCTGATGGTCATCTTCTCA AGGCGATCTTGTCCTTGGAA NM_214415
IL‑23 GCTTGCAAAGGATCCACCAA GGCTCCCCTGTGAAAATGTC NM_001130236.1
IFN‑γ CAAAGCCATCAGTGAACTCATCA TCTCTGGCCTTGGAACATAGTCT X53085
TGF‑βR1 TCAGGCTTACCATTGCTTGTTCAG CTCGCCAAACCTCTCCAAATCG NM_001038639
DEFB1 ACCGCCTCCTCCTTGTATTC GGTGCCGATCTGTTTCATCT NM_213838
DEFB2 CTGTCTGCCTCCTCTCTTCC CAGGTCCCTTCAATCCTGTT NM_214442
NF‑κB CTCGCACAAGGAGACATGAA ACTCAGCCGGAAGGCATTAT DQ834921
CD163 GCCTGTCTCATCGCATTCCT GGATTTAGCATATCCGTTTCATCTG NM_213976.1
Figure 1 Percentage of surviving animals (experiment 1). 
Groups of four pigs were inoculated intramuscularly with different 
doses of the cell culture adapted strain E75CV1: 102 HAU50, 10
4 HAU50 
and 105 HAU50; and the control group.
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(Figure 2C), indicating a total recovery from ASFV infec-
tion. The detection of ASFV-specific antibodies from 
day 18 pi by ELISA (Figure  3A) and T-cells by IFNγ-
ELISPOT at day 28 pi (Figure 3C), clearly demonstrates 
the efficient infection of every single pig i.m.i. with 104 
HAU of E75CV1, including pig 1 that showed no viremia 
(Figure  2C), or ASF-compatible signs throughout the 
Figure 2 ASFV-viremia and fever kinetics (experiment 1). 
Groups of four pigs were intramuscularly inoculated with different 
doses of the cell culture adapted strain E75CV1: 102 HAU50 (A), 10
5 
HAU50 (B) and 10
4 HAU50 (C) and both viremia and rectal temperature 
was recorded throughout the infection. ASFV‑Virus detection in indi‑
vidual sera was quantified by hemadsorption (black lines) and daily 
rectal temperature was also measured (grey lines).
Figure 3 Specific immune responses induced by E75CV1 
(experiment 1). Two groups of four pigs were intramuscularly inocu‑
lated with 104 HAU50 E75CV1 or were left as non‑immunized controls. 
The kinetics of the individual specific antibody induction was moni‑
tored by ELISA. Average and standard deviation values are shown 
(A). At day 28 pi sera from the 104 HAU50 immunized animals were 
additionally subjected to an infection inhibition assay in vitro (B) and 
ASFV‑specific T‑cells were measured at day 28 pi by an IFNγ‑ELISPOT 
assay. Average values and standard deviation shown correspond to 
three individual experiments for the E75CV1‑vaccinated (1–4) and 
control animals (C1–C4) (C).
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duration of the experiment (data not shown). In spite of 
the high titres of specific antibodies induced, sera from 
these animals were not capable to inhibit the ASFV-
infection in alveolar macrophages (Figure 3B).  
E75CV1/E75, an ideal model for the characterization 
of ASFV immunopathogenesis
In spite of its advantages, determining viral kinetics 
and the immunological responses induced throughout 
the infection by sequentially sampling (blood and nasal 
swabs) individual pigs, also have important limitations 
especially when considering full characterization of the 
in vivo pathogenesis of ASFV, a virus which mainly tar-
gets the lymphoid tissues. Therefore, a complex in  vivo 
experiment was designed (Experiment 2) aiming to com-
pare ASFV pathogenesis of cell culture adapted E75CV1 
and its virulent homologous counterpart, E75. Taking 
advantage of the optimization of the intramuscular route 
for E75CV1 in vivo inoculation (Experiment 1), a group 
of 24 pigs was i.m.i. with 104 HAU50 of E75CV1, a sec-
ond group of 18 pigs was infected using the same dose 
and route of the virulent E75 and finally a third group of 
12 pigs remained uninfected (control group). Pigs from 
the three groups were sacrificed at days 1, 3 and 7 pi 
(6 or 3 per group and day) and 6 pigs from the attenu-
ated E75CV1 and 3 from the control group were also 
sacrificed at day 31 pi. As expected for the virus and 
dose used [23], pigs infected with E75 developed severe 
ASF clinical signs, evident from day 3–5 pi, including: 
fever (Figure  4A), dyspnoea and depression. In con-
trast, the animals infected with the attenuated isolate 
(E75CV1) only developed, if at all, slight transient fever 
(Figure  4A). The viremia (Figure  4B), the viral excre-
tion (Figure  4C) and the infected macrophages counts 
in blood (Figure  4D) evolved in correlation with these 
observations. The animals infected with the attenuated 
Figure 4 Comparative in vivo infection with virulent (E75) and attenuated (E75CV1) homologous ASFV-strains (experiment 2). ASFV 
infection was monitored over time by means of rectal temperature (A), viremia as measured by haemadsorption (B), nasal viral excretion by means 
of qPCR (C) and number of infected monocytes found in blood by cytometry (D) The graphs show average values and standard deviations per six‑
animal group (**p < 0.01 and ***p < 0.001).
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isolate suffered a delay in the virus detection in sera 
(Figure  4B), in nasal excretion (Figure  4C) and in the 
infected macrophages counts in blood (Figure  4D), 
detectable only at day 7 pi and the virus titres were 4–5 
logs lower on average than those found in pigs infected 
with the E75 virulent strain, reaching up to 109 HAU50/
mL in sera. The lesions found after necropsy, mostly in 
E75-infected pigs and taking into account the macro and 
micro organ structure, relative organ weight (Figure 5A), 
virus titres found (Figure  5B), the presence of cellular 
infiltrations, apoptosis and viral presence (Table 2), con-
firmed gastrohepatic lymph node as the organ of choice 
to further compare the immunopathogenesis of both 
virus strains. Total RNA isolation from gastrohepatic 
lymph nodes obtained from each animal and day of study 
allowed the establishment of a comparative transcription 
profile of key immune mediators that were differentially 
modulated throughout the infections. Interestingly, dif-
ferences became evident as early as at day 1 pi, before 
the virus was detectable in the tissue (Figure 5B). Thus, 
compared with the 10 genes significantly up and down-
regulated by day 1 pi with E75CV1, E75 only up-regu-
lated 4, namely: IL-12p40, TGF-βR1, TNF-α and IL-21, 
with key activation markers such as sCD163, IFN-γ and 
IL-4 showing tendency towards being down-regulated 
(Figure  6A). This tendency totally reverted through 
the infection course and by day 7 pi the activation of a 
massive number of immune mediators was observed as 
demonstrated in here with the significant up-regulation 
of: IL-5, DEFB2, TLR-3, IL-6, IL-8, IL-1β, IL-21, IL-23 
and IL-10; coinciding with the cytokine storm described 
Figure 5 Gastrohepatic lymph nodes and ASFV-infection 
(experiment 2). Relative gastrohepatic lymph node weight versus 
total body weight (A) and ASFV‑titers found in gastrohepatic lymph 
node by means of qPCR (B). The figures show the average and 
the standard deviation of each six animal group (*p < 0.05 and 
**p < 0.01).
Table 2 Histopathology evaluation (experiment 2). Quan-
tification of  macrophage infiltrations (A), presence of  apop-
totic cells (B) and ASFV antigen detection (C) in gastrohepatic 
lymph node.
Results were quantified as follows: (–) no detection, (+) low, (++) moderate and 
(+++) high amounts
Animal Day 1 pi Day 3 pi Day 7 pi Day 31 pi
(A)
 Macrophage infiltration (MAC387+)
  E75 1 + + +++
2 + + +++
3 + + ++
  E75CV1 1 + + + +
2 ++ ++ ++ +
3 ++ + ++ +
  Control 1 + + + +
2 + + + +
3 + + + +
(B)
 Apoptotic cell quantification (Caspase‑3+)
  E75 1 + + +++
2 + + ++
3 + + ++
  E75CV1 1 + + + +
2 + ++ + +
3 + + + +
  Control 1 + + + +
2 + + + +
3 + + + +
(C)
 ASFV Antigen detection (p30+)
  E75 1 + ++ +++
2 – + ++
3 – ++ +++
  E75CV1 1 + – + +
2 – – + +
3 + + – ++
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during the terminal phase of acute ASF [36] (Figure 6B). 
The transcription profile observed in the gastrohe-
patic lymph nodes of E75CV1-infected pigs showed an 
inverted cytokine response when compared to that of 
E75. Converse to that described for E75, E75CV1 effi-
ciently activated an innate immune response detectable 
at day 1 pi with the significant up-regulation of CD163, 
IL-1β, IFN-γ, IL-5, IL-6, IL-12p40, TNF-α, IL-10 and 
TGF-βR1; most probably contributing to control of the 
first rounds of E75CV1-replication (Figure  6A). Con-
firming the inverse tendency described for E75, a more 
equilibrated immunological balance was observed with 
the progression of the E75CV1-infection, with 6 genes 
showing significant transcription up-regulation at day 7 
pi: IFN-γ, IL-5, TNF-α, TGF-βR1, IL-21, IL-23 and 4 extra 
genes showing a significant down-regulation: DEFB1, 
CD163, IL-13 and IL-18 (Figure 6B). Finally, pigs surviv-
ing the infection with E75CV1 showed a very consistent 
signature characterized by the up-regulation of IL-23, 
IFN-γ and NFκB and the down-regulation of IL-1β and 
IL-4 (Figure 6C).   
E75CV1, an ideal model to understand the mechanisms 
involved in protection against homologous lethal 
challenge
Once the optimal dose of E75CV1 i.m.i. was confirmed 
(Experiment 1), a final experiment was performed to 
evaluate its protective potential (Experiment 3). Con-
firming the results obtained in experiments 1 and 2, 
all pigs (8 out of 8, 4 animals per box) i.m.i. with 104 
HAU of E75CV1 survived the infection without signifi-
cant ASF clinical signs and showing none or low fever 
and viremia peaks that resolved by day 28 pi, coincid-
ing with the presence of a high level of ASFV-specific 
antibodies and a large number of ASFV-specific T-cells 
as measured by ELISA and IFNγ-ELISPOT, respectively 
Figure 6 Relative gene expression analysis in gastrohepatic lymph node of ASFV-infected pigs (experiment 2). Statistical analysis (using 
T‑Student test: *p < 0.05; **p < 0.01 and ***p < 0.001) comparing the RNA expression levels found for key regulatory molecules in gastrohepatic 
lymph nodes of animals infected with E75CV1 (attenuated) or E75 (virulent) homologous ASFV strains, relative to non‑infected animals (control 
group). Values corresponding to three pigs per group and times are represented: 1 day (A), 7 days (B) and 31 days (C) post‑infection. The colour 
grade reflects the fold‑change differences found (the higher the transcription up or down regulation, the darker the colour): the green gradient 
represents transcription down‑regulation (from −1.3 to −fivefold changes) and the red gradient represents transcription up‑regulation (from 1.3–
threefold changes). No colour (white) indicates no changes in the corresponding transcript level. No survivors from the E75 ASFV inoculated pigs 
were available at day 31 pi.
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(data not shown). At this time point, all pigs in BOX-1 
were challenged with a lethal dose of E75 and all ani-
mals in BOX-2 with a lethal dose of the BA71 virus 
strain.
E75CV1 infected animals rendered 100% of protection 
against the homologous E75 lethal challenge and impor-
tantly, the protection afforded was complete since no 
ASF-clinical signs including fever (Figure  7A), viremia 
(Figure  7B) and nasal viral excretion (Figure  7C) were 
observed at any time in any of the inoculated animals. 
Additionally, no ASF-compatible lesions were detected 
in any of the animals at necropsy, while control animals 
behaved as expected: severe signs of ASF, severe ASF-
compatible lesions found at necropsy time and high 
virus titres (in blood and nasal swabs) detectable from 
day 3 pi (Figures 7A, B and C). The control of the infec-
tion by pigs vaccinated with 104 HAU50 of E75CV1 cor-
related with the control of the cytokine storm typically 
triggered by virulent ASFV strains such as E75. Thus, 
the levels of IFN-α (Figure 8A) and TNF-α (Figure 8B) 
in pig sera remained at very low or undetectable levels 
in protected animals, while control animals showed an 
exponential increase in the sera levels of both cytokines 
after lethal challenge with the homologous E75 viru-
lent ASFV strain, as was previously described, at least 
for TNF-α [37]. Besides these two cytokines, several 
other soluble factors were found at high levels in sera 
from severely ASF-affected pigs by day 7 pi with E75, 
including IL-12 and IL-1β (data not shown) and for the 
first time, also for sCD163 (Figure  8C), an activation 
macrophage marker that has been associated with sev-
eral chronic inflammatory diseases, sepsis, and more 
recently also with certain haemorrhagic fever diseases 
caused by viruses [38]. 
Conversely, pre-immunization with E75CV1 rendered 
poor protection against BA71 lethal challenge. Two of 
the animals (50%) reached viremia levels (Figure 9A) and 
nasal viral excretion titres (Figure  9B) indistinguishable 
from those found in control pigs, while the other 2 pigs 
showed a delay in the appearance of viremia (from day 3 
to day 5 pi), reaching lower levels comparing with con-
trol group. Moreover, all the animals suffered from severe 
clinical signs of ASF, being sacrificed at day 7 pi for ethi-
cal reasons. At the time of necropsy it was not possible 
to differentiate the controls and the vaccinated animals 
(data not shown).
Intriguingly, sera and PBMCs isolated from pigs sur-
viving E75CV1 (day 28 pi), equally recognized E75 and 
BA71 in  vitro, at least using the home-made ELISA 
and IFNγ-ELISPOT assays and again, sera from these 
Figure 7 Inoculation of E75CV1 confers protection against 
homologous E75 lethal challenge (Box 1 from experiment 3). 
Groups of four pigs were either inoculated with 104 HAU50 E75CV1 or 
non‑immunized (control) and 31 days later were challenged with a 
lethal dose of 104 HAU50 of E75. The ASFV infection was montitored 
by: rectal temperature (A), virus detection in sera by hemadsorption 
(B) and nasal excretion by means of qPCR (C). The graphs show the 
average values of each group and the standard deviations (**p < 0.01 
and ***p < 0.001).
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animals were not capable of inhibiting the ASFV-infec-
tion in alveolar macrophages (data not shown). Aiming 
to further explore the mechanisms that could explain 
E75-homologous protection and the lack of cross-pro-
tection against BA71, the PBMCs from animals infected 
with E75CV1 at day 28 pi were subjected to an in vitro 
CFSE-proliferation assay using either E75 or BA71 as 
specific stimuli for three days. Interestingly, immuni-
zation with the attenuated E75CV1 induced double 
positive CD4+/CD8low T-cells capable of specifically 
recognizing both viruses, E75 and BA71 (Figure 10). In 
clear contrast, their single positive CD8high T-cells spe-
cifically proliferated almost exclusively in response to 
the homologous E75 virus, with the heterologous BA71 
provoking a poor CD8+ T-cell stimulation (Figure 10). 
A poor stimulation was also observed in response 
to both viruses for the single positive CD4+ T-cells 
(Figure 10).
Figure 8 Inoculation of E75CV1 protects against the cytokine 
storm provoked by homologous E75 lethal challenge (Box 1 
from experiment 3). Groups of four pigs were either inoculated 
with 104 HAU50 E75CV1 or non‑immunized (control) and 31 days later 
were challenged with a lethal dose of 104 HAU50 E75. The delivery of 
cytokines and soluble cellular factors to the sera of the infected pigs 
was measured throughout the ASFV‑challenge by specific ELISAs for: 
IFN‑α (A), TNF‑α (B) and sCD163 (C). Graphs show average values and 
standard deviations per group (*p < 0.05; **p < 0.01 and ***p < 0.001).
Figure 9 Inoculation of E75CV1 does not confer protection 
against heterologous BA71 lethal challenge (Box 2 from exper-
iment 3). Groups of four pigs were either inoculated with 104 HAU50 
E75CV1 (solid lines) or non‑immunized (control, discontinuous lines) 
and 31 days later were challenged with a lethal dose of 103 HAU50 
BA71. The ASFV infection was monitored by: ASFV detection in sera 
by hemadsorption (A) and nasal excretion by means of qPCR (B). The 
graphs show the values corresponding to individual pigs.
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Figure 10 The presence of specific CD8+ T cells capable of in vitro proliferation in response to a specific ASFV strain correlates with 
in vivo protection. Detection of ASFV‑specific CD4+, double positive CD4+/CD8low or CD8high proliferating T‑cells of E75CV1‑inoculated pigs at day 
28 pi, just before ASFV‑virulent challenge. The specific proliferation was performed by labeling the PBMCs with CFSE followed by in vitro stimulation 
with either E75 or BA71 ASFV strains as stimuli. PBMCs were finally stained with anti‑CD4 or anti‑CD8 antibodies and analysed by flow cytometry. 
The percentage of specific CD4+, double positive CD4+/CD8low and CD8high proliferating T‑cells is also shown.
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Discussion
The fine balance observed between surviving and death 
after ASFV infection seems to rest on multiple fac-
tors, including the pathogenicity of a particular ASFV 
strain, the initial viral dose received by the pig and the 
health status of the particular animal. Thus, receiving ten 
times more ASFV than the optimal dose of the cell cul-
ture adapted E75CV1 provoked the death of 50% of the 
pigs, corresponding with their incapability to control the 
initial rounds of replication as demonstrated with the 
detection of early viremia from day 5 pi, 3  days before 
surviving pigs. The fact that infection with 104 HAU50 of 
the virulent E75 strain also coincided with early viremia 
detectable from days 3–5 pi, correlating with an impaired 
recognition by the immune system very early after the 
infection (see below), allows us to hypothesize that a sim-
ilar scenario could also explain the fate between surviving 
and death after i.m.i. with high doses of E75CV1 (2 out of 
4 pigs dying after i.m.i. with 105HAU50 of the virus). In 
agreement with this hypothesis, the viremia and the clini-
cal signs observed and the postmortem lesions found in 
these two pigs were indistinguishable from those occur-
ring after E75-infection. The unexpected results obtained 
after inoculating pigs with the lower dose of E75CV1 
(100 HAU50) might be explained by direct in contact-
transmission, most probably with the two pigs succumb-
ing to the high infectious-dose of E75CV1. Even if this 
was the scenario, it accurately reflects what might occur 
under field conditions, with a proportion of naïve pigs 
becoming severely infected by exposure to large amounts 
of a live attenuated vaccine. Increasing biosafety tests for 
LAV prototypes might be mandatory in the future if they 
are to be commercialized. The results recently obtained 
with E75CV1 [15] and also observed with the OURT88/3 
ASFV attenuated strain [12], allow the assumption that 
the use of specific pathogen free (SPF)-pigs could become 
an ideal in  vivo model for evaluating the biosecurity of 
future live attenuated ASFV as vaccines. Infection of 
SPF-pigs with the intermediate optimal dose of E75CV1, 
albeit safe for farm pigs, resulted lethal for 100% of the 
SPF-animals [15]. The reasons behind the enhanced sen-
sitivity of SPF pigs to attenuated ASFV strains could also 
partially explain the vaccine escapes observed under field 
conditions in the past [13]. The existence of residual viru-
lence in ASFV attenuated strains has been described not 
only for naturally attenuated strains, such as E75CV1 and 
OURT 88/3 [12], but also for modified LAV generated by 
targeted depletion of virulent factors [39] and on many 
occasions this becomes complicated due to second-
ary infections attributable to the immune suppression 
induced by the virus.
With the aim of understanding the molecular mecha-
nisms involved in attenuation of E7CV1, we are currently 
in the process of sequencing E75CV1. The availability of 
the E75 complete sequence (GenBank: FN557520) should 
facilitate the identification of the molecular changes in 
the genome of E75CV1 in comparison to its closest rela-
tive, thus contributing to better define virulence factors. 
Much effort has been made in the past with distantly 
related virulent and attenuated viruses and more recently, 
with related strains with different virulence facilitating 
the comparison [40]. These results have recently been 
extended to a more refined study helping to unmask the 
genome changes occurring during the adaptation of the 
virulent Georgia 2007 ASFV strain to Vero cell and sub-
sequent attenuation [41].
We believe that performing comparative pathogenesis 
studies with two homologous strains with a unique ori-
gin, further validates the results obtained. Quantitative 
PCR results demonstrated the differential transcription 
kinetics existing between the attenuated and the viru-
lent ASFV-strains. The infection with E75 shows a tran-
scription profile quantitatively and qualitatively different 
from E75CV1 early after the infection. Thus, compared 
with the 10 genes significantly up and down-regulated by 
day 1 pi with E75CV1, E75 only up-regulated 4 of them, 
namely: IL-12p40, TGF-βR1, TNF-α and IL-21; the last 
not being significantly regulated with E75CV1 infection. 
The reduced number of immune modulators triggered 
at day 1 pi might help explaining the failure of the innate 
immune system to detect and control the first rounds of 
virus replication, thus allowing the rapid spread of the 
virus to lymphoid tissues, blood and nasals secretions. 
The lack of early recognition (day 1 pi) of the E75 virulent 
strain by the immune system might correlate with the 
observed down-regulation tendency of CD163, a putative 
ASFV receptor [42]. Conversely to what has been shown 
for E75CV1 the progression of the E75-infection resulted 
in a dramatic imbalance of the immune system by day 7 
pi, with the significant up-regulation of 9 genes, namely: 
IL-5, IL-1β, IL-6, IL-8, IL-10, IL-21, IL-23, DEFB2 and 
TLR-3. Surprisingly, the TLR-3 gene was significantly and 
exclusively up-regulated at day 7 pi, perhaps reflecting 
the incapability of the TLR-3 antagonist present in ASFV 
[43] to keep the TLR-3 signaling pathway under control 
any longer. TLR-3, an Innate Pattern Recognition Recep-
tor (IPRR) has been described as an efficient virus-sensor 
that could trigger friendly or unfriendly transduction 
cascades. The number and level of genes up-regulated 
at day 7 pi is unexpectedly high taking into account the 
damage suffered by the gastrohepatic lymph node, show-
ing an almost unrecognizable architecture with mas-
sive cellular destruction. The dramatic increase found in 
sera of almost all the immune mediators tested: TNF-α, 
IFN-α, IL-12, IL-1β and sCD163 confirm the soluble fac-
tor storm suffered by acutely infected pigs in the latter 
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phases of infection, most probably reflecting the massive 
tissue destruction found. Therefore, the dramatic activa-
tion of the immune system at day 7 pi might reflect the 
massive and disseminated fatal infection rather than a 
defensive mechanism. Unfortunately, the late detection 
of significantly high levels of sCD163 in sera at very late 
times makes its future use as an early diagnostic marker 
for ASFV unlikely. The presence of sCD163 in sera could 
however give new insight into understanding ASFV 
pathogenesis, perhaps playing an immunoregulatory role.
Conversely, the same viral dose of E75CV1 provoked 
the immediate activation of the immune system, reflect-
ing most probably an efficient priming of the innate 
immune system, a key event for further mounting an 
efficient adaptive immune response, detectable at late 
time points post-infection. A careful dissection of the 
transcription profile by day 1 pi in tissues from E75CV1-
infected pigs, allowed the confirmation of the significant 
up-regulation of CD163, IL-1β, IFN-γ, IL-5, IL-6, IL-10, 
IL-12p40, TNF-α and TGF-βR1 and the down-regula-
tion of DEFB2, immediately after E75CV1 infection. 
The up-regulation of CD163 has been associated with 
monocytes maturation into macrophages, and fits with 
the ability of ASFV to interact with the surface CD163 
for viral entry [42]. The role of CD163 as receptor for 
ASFV entry has been proposed but not universally sup-
ported since reports demonstrated efficient infection of 
macrophages that do not express CD163 [44]. Regard-
less of this, the virus interaction with CD163 and other 
cell surface molecules most probably trigger the overex-
pression of the genes coding several pro-inflammatory 
cytokines: IL-1β, IFN-γ, IL-5, IL-6, IL-12p40 and TNF-
α; and also some anti-inflammatory mediators such as 
IL-10 and TGF-βR1 that might contribute to control-
ling the first rounds of virus replication while avoid-
ing harmful inflammation. With the progression of the 
infection a more equilibrated immunological balance is 
observed, with 6 genes showing significant transcrip-
tion up-regulation: IFN-γ, IL-5, TNF-α, TGF-βR1, IL-21 
and IL-23 and 4 extra genes showing significant down-
regulation: DEFB1, CD163, IL-13 and IL-18. By day 31 
pi, once the E75CV1 infection has been resolved and the 
memory specific B and T-cell responses have been estab-
lished, a very tight regulation of the immune response 
was observed with only 2 genes being significantly up-
regulated: IL-23 and NFκB; and another two signifi-
cantly down-regulated: IL-1β and IL-4, signature of Th 
17-like responses. The continuous down-regulation suf-
fered by the IL-4 transcript reached its maximum level 
and significance at day 31 pi with E75CV1, coincid-
ing with significant up-regulation of IL-23 that in turn 
has been described to promote the Th17 switch [45]. 
This together with the continuous activation of IFN-γ 
and TGF-βR1 throughout E75CV1 infection could also 
contribute to the continuous transformation of Th1 to 
Th17 cells, also previously described [46]. Th17 were 
first described as a CD4+ T-cell subset associated with 
chronic inflammatory processes, autoimmunity, allergy 
and transplant rejection [47]. Today we know that this 
is true if inappropriate, excessive, and non-specific Th17 
effector responses are triggered, while on other occa-
sions the induction of specific Th17/Th1 (IL-17+/IFN-γ+ 
cells) could exert beneficial effects. Thus, T(H)1/T(H)17 
have been postulated as key cell subsets to fight against 
infections such as tuberculosis [48]. Thus, lacking 
(T(H)1/T(H)17)-cells has been described as a risk fac-
tor for the development of active tuberculosis in patients 
with HIV-1 infection and has been proposed as a useful 
biomarker in the development of tuberculosis vaccines. 
Further work will be needed to confirm the specific-
ity and the role of Th17 cells in protection. The partial 
transcription profile shown here will be completed by 
performing complementary micro array and proteomic 
assays (work in progress).
As described in the introduction together with 
the innate immune responses, both specific B and 
T-cell responses play important roles in the protec-
tion afforded [30], these also being efficiently primed 
by our E75CV1 model. Unfortunately, all attempts to 
demonstrate the presence of specific antibodies capa-
ble of inhibiting the ASFV infection in  vitro failed 
[28]. Similarly, the identical sequences of the E75 and 
BA71 haemagglutinin also failed to define the cross 
protection failure using a differential hemadsorption 
inhibition assay, as recently postulated for predicting 
the efficacy of ASFV vaccines [49]. Although no sig-
nificant differences were observed by IFNγ-ELISPOT 
in response to the in vitro stimulation with either the 
homologous E75 or the heterologous BA71 viruses, 
we could not rule-out that these differences exist, as 
has been previously reported [12]. Technical limita-
tions of our home-made IFNγ-ELISPOT assay per-
formed with half a million PBMCs, did not allow a 
precise quantification of the specific spots found in 
response to each specific stimuli. Independent of 
these differences, one of the most relevant conclu-
sions of the present work is the definition of a new 
in vitro correlation for ASFV protection to be added 
to the ones that already exist. The fact that CD4+ 
and double positive CD4+/CD8low T-cells, defined as 
memory T-cells [30] indistinguishably proliferated in 
response to both homologous and heterologous virus 
fits with the IFNγ-ELISPOT data presented here. 
Conversely, the strong correlation between protection 
and in  vitro recognition of strain-specific CD8high 
T-cells, cytotoxic T-cells [30] is novel and might have 
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important implications for the future design of vac-
cines. Cross-protective vaccines should be able to 
induce specific CTL responses against common anti-
gens, an element that seems to be impaired in the 
LAV tested so far against ASFV. It has recently been 
published results demonstrating the establishment 
of a strong CD8+ T-cell immunodominance during 
ASFV recovery in  vivo that could be overcome by 
prior immunization with subunit vaccines [30], a fact 
previously described for many pathogens. Several can 
be the reasons explaining the narrow repertoire of 
specific CD8+ T-cells induced, most probably being 
multifactorial and regulated by IFN-γ as explained for 
many other viruses [50]. The intrinsic mechanisms 
explaining ASF-immunodominance are being further 
studied with the aim of extracting useful lessons for 
future vaccine developments against ASFV.
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